open Menu
Search icon

SMOOSE

Publikationen

2024

Dampmann, M., S. Flossdorf, J. Keyl, H. C. Reinhardt, and C. Hanoun (2024). "Single-Center Experience of Patients with Plasma Cell Leukemia in the Era of New Therapeutics." Acta Haematologica: 1–8. doi.org/10.1159/000539223.

Dobersalske, C., L. Rauschenbach, Y. Hua, C. Berliner, A. Steinbach, A. Grüneboom, K. D. Kokkaliaris, D. H. Heiland, P. Berger, S. Langer, C. L. Tan, M. Stenzel, S. Landolsi, F. Weber, M. Darkwah Oppong, R. A. Werner, H. Gull, T. Schröder, T. Linsenmann, A. K. Buck, M. Gunzer, M. Stuschke, K. Keyvani, M. Forsting, M. Glas, J. Kipnis, D. A. Steindler, H. C. Reinhardt, E. W. Green, M. Platten, A. Tasdogan, K. Herrmann, F. Rambow, I. Cima, U. Sure, and B. Scheffler (2024). "Cranioencephalic functional lymphoid units in glioblastoma." Nature Medicine: 1–10. doi.org/10.1038/s41591-024-03152-x.

Flümann, R., J. Hansen, J. Meinel, P. Pfeiffer, H. Goldfarb Wittkopf, A. Lütz, J. Wirtz, M. Möllmann, T. Zhou, A. Tabatabai, T. Lohmann, M. Jauch, F. Beleggia, B. Pelzer, F. Ullrich, S. Höfmann, A. Arora, T. Persigehl, R. Buettner, B. von Tresckow, S. Klein, R. D. Jachimowicz, H. C. Reinhardt, and G. Knittel (2024). "An inducible Cd79b mutation confers ibrutinib sensitivity in mouse models of Myd88-driven diffuse large B-cell lymphoma." Blood Adv. doi.org/10.1182/bloodadvances.2023011213.

Knittel, G., and H. C. Reinhardt (2024). "XPO1-Mediated mRNA Export of Genome Maintenance Regulators Drives Chemotherapy Resistance in Aggressive Lymphoma." Cancer Res. 84(1): 3–5. doi.org/10.1158/0008-5472.CAN-23-2966.

2023

Alborzinia, H., Z. Chen, U. Yildiz, F. P. Freitas, F. C. E. Vogel, J. P. Varga, J. Batani, C. Bartenhagen, W. Schmitz, G. Büchel, B. Michalke, J. Zheng, S. Meierjohann, E. Girardi, E. Espinet, A. F. Flórez, A. F. dos Santos, N. Aroua, T. Cheytan, J. Haenlin, L. Schlicker, T. N. X. da Silva, A. Przybylla, P. Zeisberger, G. Superti-Furga, M. Eilers, M. Conrad, M. Fabiano, U. Schweizer, M. Fischer, A. Schulze, A. Trumpp, and J. P. F. Angeli (2023). "LRP8‐mediated selenocysteine uptake is a targetable vulnerability in MYCN‐amplified neuroblastoma." EMBO Mol. Med. doi.org/10.15252/emmm.202318014.

Flümann, R., J. Hansen, B. W. Pelzer, P. Nieper, T. Lohmann, I. Kisis, T. Riet, V. Kohlhas, P.-H. Nguyen, M. Peifer, N. Abedpour, G. Bosco, R. K. Thomas, M. Kochanek, J. Knüfer, L. Jonigkeit, F. Beleggia, A. Holzem, R. Büttner, P. Lohneis, J. Meinel, M. Ortmann, T. Persigehl, M. Hallek, D. P. Calado, M. Chmielewski, S. Klein, J. R. Göthert, B. Chapuy, B. Zevnik, F. T. Wunderlich, B. von Tresckow, R. D. Jachimowicz, A. M. Melnick, H. C. Reinhardt, and G. Knittel (2023). "Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies." Blood Cancer Discov. 4(1): 78–97. doi.org/10.1158/2643-3230.BCD-22-0007.

Grabe, T., K. Jeyakumar, J. Niggenaber, T. Schulz, S. Koska, S. Kleinbölting, M. E. Beck, M. P. Müller, and D. Rauh (2023). "Addressing the Osimertinib Resistance Mutation EGFR-L858R/C797S with Reversible Aminopyrimidines." ACS Med Chem Lett 2023. doi.org/10.1021/acsmedchemlett.2c00514.

Knittel, G., and H. C. Reinhardt (2023). "XPO1-mediated mRNA export of genome maintenance regulators drives chemotherapy resistance in aggressive lymphoma." Cancer Research. doi.org/10.1158/0008-5472.CAN-23-2966.

Müller, N., C. Lorenz, J. Ostendorp, F. S. Heisel, U. P. Friese, M. Cartolano, D. Plenker, H. L. Tumbrink, A. Heimsoeth, P. Baedeker, S. Ortiz-Cuaran, J. Weiss, R. Büttner, M. Peifer, R. K. Thomas, M. L. Sos, J. Berg, and J. Brägelmann (2023). "Characterizing evolutionary dynamics reveals strategies to exhaust the spectrum of subclonal resistance in EGFR-mutant lung cancer." Cancer Res. doi.org/10.1158/0008-5472.CAN-22-2605.

Rosswog, C., J. Fassunke, A. Ernst, B. Schömig-Markiefka, S. Merkelbach-Bruse, C. Bartenhagen, M. Cartolano, S. Ackermann, J. Theissen, M. Blattner-Johnson, B. Jones, K. Schramm, J. Altmüller, P. Nürnberg, M. Ortmann, F. Berthold, M. Peifer, R. Büttner, F. Westermann, J. H. Schulte, T. Simon, B. Hero, and M. Fischer (2023). "Genomic ALK alterations in primary and relapsed neuroblastoma." Br J Cancer: 1–13. doi.org/10.1038/s41416-023-02208-y.

Tabatabai, A., A. Arora, S. Höfmann, M. Jauch, B. von Tresckow, J. Hansen, R. Flümann, R. D. Jachimowicz, S. Klein, H. C. Reinhardt, and G. Knittel (2023). "Mouse models of diffuse large B cell lymphoma." Frontiers in Immunology 14. doi.org/10.3389/fimmu.2023.1313371.

2022

Borchmann, S., C. Selenz, M. Lohmann, H. Ludwig, A. Gassa, J. Brägelmann, P. Lohneis, L. Meder, J. Mattlener, S. Breid, M. Nill, J. Fassunke, A. J. Wisdom, A. Compes, B. Gathof, H. Alakus, D. Kirsch, K. Hekmat, R. Büttner, H. C. Reinhardt, M. Hallek, and R. T. Ullrich (2022). "Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors." J ImmunoTher Cancer 10(10): e004781. doi.org/10.1136/jitc-2022-004781.

Fischer-Mertens, J., F. Otte, A. Roderwieser, C. Rosswog, Y. Kahlert, L. Werr, A.-M. Hellmann, M. Berding, B. Chiu, C. Bartenhagen, and M. Fischer (2022). "Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models." Cell Oncol: 1–13. doi.org/10.1007/s13402-022-00702-8.

Izquierdo, E., D. Vorholt, S. Blakemore, B. Sackey, J. L. Nolte, V. Barbarino, J. Schmitz, N. Nickel, D. Bachurski, L. Lobastova, M. Nikolic, M. Michalik, R. Brinker, O. Merkel, M. Franitza, T. Georgomanolis, R. Neuhaus, M. Koch, N. Nasada, G. Knittel, B. Chapuy, N. Ludwig, E. Meese, L. Frenzel, H. C. Reinhardt, M. Peifer, R. Rebollido-Rios, H. Bruns, M. Krüger, M. Hallek, and C. P. Pallasch (2022). "Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies." Blood 139(25): 3617–3629. doi.org/10.1182/blood.2021014007.

Meeser, A., C. Bartenhagen, L. Werr, A.-M. Hellmann, Y. Kahlert, N. Hemstedt, P. Nürnberg, J. Altmüller, S. Ackermann, B. Hero, T. Simon, M. Peifer, M. Fischer, and C. Rosswog (2022). "Reliable assessment of telomere maintenance mechanisms in neuroblastoma." Cell Biosci 12(1): 1–16. doi.org/10.1186/s13578-022-00896-2.

Ratz, L., C. Brambillasca, L. Bartke, M. A. Huetzen, J. Goergens, O. Leidecker, R. D. Jachimowicz, M. van de Ven, N. Proost, B. Siteur, R. de Korte-Grimmerink, P. Bouwman, E. M. Pulver, R. de Bruijn, J. Isensee, T. Hucho, G. Pandey, M. van Lohuizen, P. Mallmann, H. C. Reinhardt, J. Jonkers, and J. Puppe (2022). "Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer." Breast Cancer Research 24(1): 41. doi.org/10.1186/s13058-022-01534-y.

Thimm, A., A. Carpinteiro, S. Oubari, M. Papathanasiou, P. Luedike, L. Kessler, C. Rischpler, T. Blau, H. C. Reinhardt, T. Rassaf, H. Schmidt, C. Kleinschnitz, and T. Hagenacker (2022). "Prevalence and predictors of neurological manifestations in systemic AL amyloidosis." J Neurol Sci 440: 120341. doi.org/10.1016/j.jns.2022.120341.

Thomalla, D., L. Beckmann, C. Grimm, M. Oliverio, L. Meder, C. D. Herling, P. Nieper, T. Feldmann, O. Merkel, E. Lorsy, A. da Palma Guerreiro, J. von Jan, I. Kisis, E. Wasserburger, J. Claasen, E. Faitschuk-Meyer, J. Altmüller, P. Nürnberg, T.-P. Yang, M. Lienhard, R. Herwig, K.-A. Kreuzer, C. P. Pallasch, R. Buettner, S. C. Schäfer, J. Hartley, H. Abken, M. Peifer, H. Kashkar, G. Knittel, B. Eichhorst, R. T. Ullrich, M. Herling, H. C. Reinhardt, Prof., M. Hallek, M. R. Schweiger, and L. P. Frenzel (2022). "Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies." Blood. doi.org/10.1182/blood.2021014304.

Wiedemann, B., D. Kamps, L. Depta, J. Weisner, J. Cvetreznik, S. Tomassi, S. Gentz, J.-E. Hoffmann, M. P. Müller, O. Koch, L. Dehmelt, and D. Rauh (2022). "Design and synthesis of Nrf2-derived hydrocarbon stapled peptides for the disruption of protein-DNA-interactions." PLoS One 17(6): e0267651. doi.org/10.1371/journal.pone.0267651.

Wilke, A. C., C. Doebele, A. Zindel, K. S. Lee, S. A. Rieke, M. Ceribelli, F. Comoglio, J. D. Phelan, J. Q. Wang, Y. Pikman, D. Jahn, B. Haupl, C. Schneider, S. Scheich, F. A. Tosto, H. Bohnenberger, P. Stauder, F. Schnutgen, M. Slabicki, Z. A. Coulibaly, S. Wolf, K. Bojarczuk, B. Chapuy, C. H. Brandts, P. Stroebel, C. A. Lewis, M. Engelke, X. Xu, H. Kim, T. H. Dang, R. Schmitz, D. J. Hodson, K. Stegmaier, H. Urlaub, H. Serve, C. A. Schmitt, F. Kreuz, G. Knittel, J. D. Rabinowitz, H. C. Reinhardt, M. G. Vander Heiden, C. Thomas, L. M. Staudt, T. Zenz, and T. Oellerich (2022). "SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma." Blood 139(4): 538-553. www.ncbi.nlm.nih.gov/pubmed/34624079.

2021

Kanne, J., M. Hussong, J. Isensee, Á. Muñoz-López, J. Wolffgramm, F. Heß, C. Grimm, S. Bessonov, L. Meder, J. Wang, H. C. Reinhardt, M. Odenthal, T. Hucho, R. Büttner, D. Summerer and M. R. Schweiger (2021). "Pericentromeric Satellite III transcripts induce etoposide resistance." Cell Death Dis 12(530): 1–15. SMOOSE doi.org/10.1038/s41419-021-03810-9.

Rosswog, C., C. Bartenhagen, A. Welte, Y. Kahlert, N. Hemstedt, W. Lorenz, M. Cartolano, S. Ackermann, S. Perner, W. Vogel, J. Altmüller, P. Nürnberg, F. Hertwig, G. Göhring, E. Lilienweiss, A. M. Stütz, J. O. Korbel, R. K. Thomas, M. Peifer and M. Fischer (2021). "Chromothripsis followed by circular recombination drives oncogene amplification in human cancer." Nat Genet 53: 1673–1685. SMOOSE, SysMED-NB & InCa doi.org/10.1038/s41588-021-00951-7.

2020

Cartolano, M., N. Abedpour, V. Achter, T.-P. Yang, S. Ackermann, M. Fischer and M. Peifer (2020). "CaMuS: simultaneous fitting and de novo imputation of cancer mutational signature." Sci Rep 10(19316): 1–10. SMOOSE & InCa & SysMed-NB doi.org/10.1038/s41598-020-75753-8.

Lategahn, J., J. Hardick, T. Grabe, J. Niggenaber, K. Jeyakumar, M. Keul, H. L. Tumbrink, C. Becker, L. Hodson, T. Kirschner, P. Klövekorn, J. Ketzer, M. Baumann, S. Terheyden, A. Unger, J. Weisner, M. P. Müller, W. A. L. van Otterlo, S. Bauer and D. Rauh (2020). "Targeting Her2-insYVMA with Covalent Inhibitors—A Focused Compound Screening and Structure-Based Design Approach." J Med Chem 63(20): 11725–11755. SMOOSE & InCa doi.org/10.1021/acs.jmedchem.0c00870.

Niggenaber, J., L. Heyden, T. Grabe, M. P. Müller, J. Lategahn and D. Rauh (2020). "Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands." ACS Med Chem Lett 2020. SMOOSE doi.org/10.1021/acsmedchemlett.0c00472.

Roser, P., J. Weisner, J. Stehle, D. Rauh and M. Drescher (2020). "Conformational selection vs. induced fit: insights into the binding mechanisms of p38α MAP Kinase inhibitors." Chem Commun. SMOOSE doi.org/10.1039/D0CC02539A.

2019

Ackermann, S. and Fischer, M. (2019). "Telomere Maintenance in Pediatric Cancer." Int J Mol Sci 20(23). www.ncbi.nlm.nih.gov/pubmed/31757062.

Campbell, K., Shyr, D., Bagatell, R., Fischer, M., Nakagawara, A., Nieto, A. C., Brodeur, G. M., Matthay, K. K., London, W. B. and DuBois, S. G. (2019). "Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project." Pediatr Blood Cancer 66(8): e27819. www.ncbi.nlm.nih.gov/pubmed/31115156.

Castiglione, R., Alidousty, C., Holz, B., Wagener, S., Baar, T., Heydt, C., Binot, E., Zupp, S., Kron, A., Wolf, J., Merkelbach-Bruse, S., Reinhardt, H. C., Buettner, R. and Schultheis, A. M. (2019). "Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies." Modern Pathology 32(5): 627-638. www.ncbi.nlm.nih.gov/pubmed/30459450.

Dammert, M. A., Bragelmann, J., Olsen, R. R., Bohm, S., Monhasery, N., Whitney, C. P., Chalishazar, M. D., Tumbrink, H. L., Guthrie, M. R., Klein, S., Ireland, A. S., Ryan, J., Schmitt, A., Marx, A., Ozretic, L., Castiglione, R., Lorenz, C., Jachimowicz, R. D., Wolf, E., Thomas, R. K., Poirier, J. T., Buttner, R., Sen, T., Byers, L. A., Reinhardt, H. C., Letai, A., Oliver, T. G. and Sos, M. L. (2019). "MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer." Nat Commun 10(1): 3485. www.ncbi.nlm.nih.gov/pubmed/31375684.

Grimm, C., Fischer, A., Farrelly, A. M., Kalachand, R., Castiglione, R., Wasserburger, E., Hussong, M., Schultheis, A. M., Altmüller, J., Thiele, H., Reinhardt, H. C., Hauschulz, K., Hennessy, B. T., Herwig, R., Lienhard, M., Buettner, R. and Schweiger, M. R. (2019). "Combined Targeted Re-Sequencing of Cytosine DNA Methylation and Mutations of DNA Repair Genes with Potential Use for PARP1 Inhibitor Sensitivity Testing." The Journal of molecular diagnostics: JMD 21(2): 198-213. www.ncbi.nlm.nih.gov/pubmed/30576872.

Jachimowicz, R. D., Beleggia, F., Isensee, J., Velpula, B. B., Goergens, J., Bustos, M. A., Doll, M. A., Shenoy, A., Checa-Rodriguez, C., Wiederstein, J. L., Baranes-Bachar, K., Bartenhagen, C., Hertwig, F., Teper, N., Nishi, T., Schmitt, A., Distelmaier, F., Lüdecke, H.-J., Albrecht, B., Krüger, M., Schumacher, B., Geiger, T., Hoon, D. S. B., Huertas, P., Fischer, M., Hucho, T., Peifer, M., Ziv, Y., Reinhardt, H. C., Wieczorek, D. and Shiloh, Y. (2019). "UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors." Cell. www.ncbi.nlm.nih.gov/pubmed/30612738.

Jachimowicz, R. D., Goergens, J. and Reinhardt, H. C. (2019). "DNA double-strand break repair pathway choice - from basic biology to clinical exploitation." Cell Cycle 18(13): 1423-1434. www.ncbi.nlm.nih.gov/pubmed/31116084.

Lategahn, J., Keul, M., Klovekorn, P., Tumbrink, H. L., Niggenaber, J., Muller, M. P., Hodson, L., Flasshoff, M., Hardick, J., Grabe, T., Engel, J., Schultz-Fademrecht, C., Baumann, M., Ketzer, J., Muhlenberg, T., Hiller, W., Gunther, G., Unger, A., Muller, H., Heimsoeth, A., Golz, C., Blank-Landeshammer, B., Kollipara, L., Zahedi, R. P., Strohmann, C., Hengstler, J. G., van Otterlo, W. A. L., Bauer, S. and Rauh, D. (2019). "Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S." Chem Sci 10(46): 10789-10801. www.ncbi.nlm.nih.gov/pubmed/31857889.

Nieroda, L., Maas, L., Thiebes, S., Lang, U., Sunyaev, A., Achter, V. and Peifer, M. (2019). "iRODS metadata management for a cancer genome analysis workflow." BMC Bioinformatics 20(1): 29. www.ncbi.nlm.nih.gov/pubmed/30646845.

Quambusch, L., Landel, I., Depta, L., Weisner, J., Uhlenbrock, N., Muller, M. P., Glanemann, F., Althoff, K., Siveke, J. T. and Rauh, D. (2019). "Covalent-Allosteric Inhibitors to Achieve Akt Isoform-Selectivity." Angewandte Chemie-International Edition 58(52): 18823-18829. www.ncbi.nlm.nih.gov/pubmed/31584233.

Uhlenbrock, N., Smith, S., Weisner, J., Landel, I., Lindemann, M., Le, T. A., Hardick, J., Gontla, R., Scheinpflug, R., Czodrowski, P., Janning, P., Depta, L., Quambusch, L., Muller, M. P., Engels, B. and Rauh, D. (2019). "Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt." Chem Sci 10(12): 3573-3585. www.ncbi.nlm.nih.gov/pubmed/30996949.

Weisner, J., Landel, I., Reintjes, C., Uhlenbrock, N., Trajkovic-Arsic, M., Dienstbier, N., Hardick, J., Ladigan, S., Lindemann, M., Smith, S., Quambusch, L., Scheinpflug, R., Depta, L., Gontla, R., Unger, A., Muller, H., Baumann, M., Schultz-Fademrecht, C., Gunther, G., Maghnouj, A., Muller, M. P., Pohl, M., Teschendorf, C., Wolters, H., Viebahn, R., Tannapfel, A., Uhl, W., Hengstler, J. G., Hahn, S. A., Siveke, J. T. and Rauh, D. (2019). "Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer." Cancer Res 79(9): 2367-2378. www.ncbi.nlm.nih.gov/pubmed/30858154.

Wolle, P., Engel, J., Smith, S., Goebel, L., Hennes, E., Lategahn, J. and Rauh, D. (2019). "Characterization of Covalent Pyrazolopyrimidine-MKK7 Complexes and a Report on a Unique DFG-in/Leu-in Conformation of Mitogen-Activated Protein Kinase Kinase 7 (MKK7)." J Med Chem 62(11): 5541-5546. www.ncbi.nlm.nih.gov/pubmed/31083997.

Wolle, P., Hardick, J., Cronin, S. J. F., Engel, J., Baumann, M., Lategahn, J., Penninger, J. M. and Rauh, D. (2019). "Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors." J Med Chem. www.ncbi.nlm.nih.gov/pubmed/30768270.

2018

Ackermann, S., Cartolano, M., Hero, B., Welte, A., Kahlert, Y., Roderwieser, A., Bartenhagen, C., Walter, E., Gecht, J., Kerschke, L., Volland, R., Menon, R., Heuckmann, J. M., Gartlgruber, M., Hartlieb, S., Henrich, K.-O., Okonechnikov, K., Altmüller, J., Nürnberg, P., Lefever, S., Wilde, B. d., Sand, F., Ikram, F., Rosswog, C., Fischer, J., Theissen, J., Hertwig, F., Singhi, A. D., Simon, T., Vogel, W., Perner, S., Krug, B., Schmidt, M., Rahmann, S., Achter, V., Lang, U., Vokuhl, C., Ortmann, M., Büttner, R., Eggert, A., Speleman, F., O’Sullivan, R. J., Thomas, R. K., Berthold, F., Vandesompele, J., Schramm, A., Westermann, F., Schulte, J. H., Peifer, M. and Fischer, M. (2018). "A mechanistic classification of clinical phenotypes in neuroblastoma." Science 362(6419): 1165-1170. www.ncbi.nlm.nih.gov/pubmed/30523111.

Cun, Y., Yang, T.-P., Achter, V., Lang, U. and Peifer, M. (2018). "Copy-number analysis and inference of subclonal populations in cancer genomes using Sclust." Nature Protocols 13(6): 1488-1501. www.nature.com/articles/nprot.2018.033.

Depuydt, P., Boeva, V., Hocking, T. D., Cannoodt, R., Ambros, I. M., Ambros, P. F., Asgharzadeh, S., Attiyeh, E. F., Combaret, V., Defferrari, R., Fischer, M., Hero, B., Hogarty, M. D., Irwin, M. S., Koster, J., Kreissman, S., Ladenstein, R., Lapouble, E., Laureys, G., London, W. B., Mazzocco, K., Nakagawara, A., Noguera, R., Ohira, M., Park, J. R., Potschger, U., Theissen, J., Tonini, G. P., Valteau-Couanet, D., Varesio, L., Versteeg, R., Speleman, F., Maris, J. M., Schleiermacher, G. and De Preter, K. (2018). "Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients." J Natl Cancer Inst 110(10): 1084-1093. www.ncbi.nlm.nih.gov/pubmed/29514301.

Drapkin, B. J., George, J., Christensen, C. L., Mino-Kenudson, M., Dries, R., Sundaresan, T., Phat, S., Myers, D. T., Zhong, J., Igo, P., Hazar-Rethinam, M. H., Licausi, J. A., Gomez-Caraballo, M., Kem, M., Jani, K. N., Azimi, R., Abedpour, N., Menon, R., Lakis, S., Heist, R. S., Büttner, R., Haas, S., Sequist, L. V., Shaw, A. T., Wong, K.-K., Hata, A. N., Toner, M., Maheswaran, S., Haber, D. A., Peifer, M., Dyson, N., Thomas, R. K. and Farago, A. F. (2018). "Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts." Cancer Discovery 8(5): 600-615. www.ncbi.nlm.nih.gov/pubmed/29483136.

Fassunke, J., Müller, F., Keul, M., Michels, S., Dammert, M. A., Schmitt, A., Plenker, D., Lategahn, J., Heydt, C., Brägelmann, J., Tumbrink, H. L., Alber, Y., Klein, S., Heimsoeth, A., Dahmen, I., Fischer, R. N., Scheffler, M., Ihle, M. A., Priesner, V., Scheel, A. H., Wagener, S., Kron, A., Frank, K., Garbert, K., Persigehl, T., Püsken, M., Haneder, S., Schaaf, B., Rodermann, E., Engel-Riedel, W., Felip, E., Smit, E. F., Merkelbach-Bruse, S., Reinhardt, H. C., Kast, S. M., Wolf, J., Rauh, D., Büttner, R. and Sos, M. L. (2018). "Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors." Nature Communications 9(1): 4655. www.ncbi.nlm.nih.gov/pubmed/30405134.

George, J., Walter, V., Peifer, M., Alexandrov, L. B., Seidel, D., Leenders, F., Maas, L., Müller, C., Dahmen, I., Delhomme, T. M., Ardin, M., Leblay, N., Byrnes, G., Sun, R., De Reynies, A., McLeer-Florin, A., Bosco, G., Malchers, F., Menon, R., Altmüller, J., Becker, C., Nürnberg, P., Achter, V., Lang, U., Schneider, P. M., Bogus, M., Soloway, M. G., Wilkerson, M. D., Cun, Y., McKay, J. D., Moro-Sibilot, D., Brambilla, C. G., Lantuejoul, S., Lemaitre, N., Soltermann, A., Weder, W., Tischler, V., Brustugun, O. T., Lund-Iversen, M., Helland, Å., Solberg, S., Ansén, S., Wright, G., Solomon, B., Roz, L., Pastorino, U., Petersen, I., Clement, J. H., Sänger, J., Wolf, J., Vingron, M., Zander, T., Perner, S., Travis, W. D., Haas, S. A., Olivier, M., Foll, M., Büttner, R., Hayes, D. N., Brambilla, E., Fernandez-Cuesta, L. and Thomas, R. K. (2018). "Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors." Nature Communications 9(1): 1048. www.ncbi.nlm.nih.gov/pubmed/29535388.

Herling, C. D., Abedpour, N., Weiss, J., Schmitt, A., Jachimowicz, R. D., Merkel, O., Cartolano, M., Oberbeck, S., Mayer, P., Berg, V., Thomalla, D., Kutsch, N., Stiefelhagen, M., Cramer, P., Wendtner, C.-M., Persigehl, T., Saleh, A., Altmüller, J., Nürnberg, P., Pallasch, C., Achter, V., Lang, U., Eichhorst, B., Castiglione, R., Schäfer, S. C., Büttner, R., Kreuzer, K.-A., Reinhardt, H. C., Hallek, M., Frenzel, L. P. and Peifer, M. (2018). "Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia." Nature Communications 9(1): 727. www.ncbi.nlm.nih.gov/pubmed/29463802.

Knittel, G., Rehkämper, T., Nieper, P., Schmitt, A., Flümann, R. and Reinhardt, H. C. (2018). "DNA damage pathways and B-cell lymphomagenesis." Current Opinion in Hematology 25(4): 315-322. www.ncbi.nlm.nih.gov/pubmed/29702521.

Lategahn, J., Keul, M. and Rauh, D. (2018). "Lessons To Be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer." Angew Chem Int Ed Engl 57(9): 2307-2313. www.ncbi.nlm.nih.gov/pubmed/29178586.

Macheleidt, I. F., Dalvi, P. S., Lim, S.-Y., Meemboor, S., Meder, L., Käsgen, O., Müller, M., Kleemann, K., Wang, L., Nürnberg, P., Rüsseler, V., Schäfer, S. C., Mahabir, E., Büttner, R. and Odenthal, M. (2018). "Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations." Molecular Oncology 12(11): 1965-1979. www.ncbi.nlm.nih.gov/pubmed/30220105.

Meder, L., König, K., Dietlein, F., Macheleidt, I., Florin, A., Ercanoglu, M. S., Rommerscheidt-Fuss, U., Koker, M., Schön, G., Odenthal, M., Klein, F., Büttner, R., Schulte, J. H., Heukamp, L. C. and Ullrich, R. T. (2018). "LIN28B enhanced tumorigenesis in an autochthonous KRASG12V-driven lung carcinoma mouse model." Oncogene 37(20): 2746-2756. www.ncbi.nlm.nih.gov/pubmed/29503447.

Meder, L., Schuldt, P., Thelen, M., Schmitt, A., Dietlein, F., Klein, S., Borchmann, S., Wennhold, K., Vlasic, I., Oberbeck, S., Riedel, R., Florin, A., Golfmann, K., Schlößer, H. A., Odenthal, M., Buettner, R., Wolf, J., Hallek, M., Herling, M., von Bergwelt-Baildon, M., Reinhardt, H. C. and Ullrich, R. T. (2018). "Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer." Cancer Research 78(15): 4270-4281. www.ncbi.nlm.nih.gov/pubmed/29776963.

Plenker, D., Bertrand, M., de Langen, A. J., Riedel, R., Lorenz, C., Scheel, A. H., Müller, J., Brägelmann, J., Daßler-Plenker, J., Kobe, C., Persigehl, T., Kluge, A., Wurdinger, T., Schellen, P., Hartmann, G., Zacherle, T., Menon, R., Thunnissen, E., Büttner, R., Griesinger, F., Wolf, J., Heukamp, L., Sos, M. L. and Heuckmann, J. M. (2018). "Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients." Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 24(6): 1337-1343. www.ncbi.nlm.nih.gov/pubmed/29284707.

Schmitt, A., Feldmann, G., Zander, T. and Reinhardt, H. C. (2018). "Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma." Oncology Research and Treatment 41(10): 619-625. www.ncbi.nlm.nih.gov/pubmed/30286473.

Tesch, R., Becker, C., Müller, M. P., Beck, M. E., Quambusch, L., Getlik, M., Lategahn, J., Uhlenbrock, N., Costa, F. N., Polêto, M. D., de Sena Murteira Pinheiro, P., Rodrigues, D. A., Sant'Anna, C. M. R., Ferreira, F. F., Verli, H., Fraga, C. A. M. and Rauh, D. (2018). "An Unusual Intramolecular Halogen Bond Guides Conformational Selection." Angewandte Chemie (International Ed. in English). www.ncbi.nlm.nih.gov/pubmed/29873877.

Welcker, D., Jain, M., Khurshid, S., Jokic, M., Hohne, M., Schmitt, A., Frommolt, P., Niessen, C. M., Spiro, J., Persigehl, T., Wittersheim, M., Buttner, R., Fanciulli, M., Schermer, B., Reinhardt, H. C., Benzing, T. and Hopker, K. (2018). "AATF suppresses apoptosis, promotes proliferation and is critical for Kras-driven lung cancer." Oncogene 37(11): 1503-1518. www.ncbi.nlm.nih.gov/pubmed/29321668.

Wiedemann, B., Weisner, J. and Rauh, D. (2018). "Chemical modulation of transcription factors." MedChemComm 9(8): 1249-1272. www.ncbi.nlm.nih.gov/pubmed/30151079.

Wolle, P., Müller, M. P. and Rauh, D. (2018). "Augmented Reality in Scientific Publications-Taking the Visualization of 3D Structures to the Next Level." ACS chemical biology 13(3): 496-499. www.ncbi.nlm.nih.gov/pubmed/29544257.

Wolle, P., Weisner, J., Keul, M., Landel, I., Lategahn, J. and Rauh, D. (2018). "RASPELD to Perform High-End Screening in an Academic Environment Toward the Development of Cancer Therapeutics." ChemMedChem. www.ncbi.nlm.nih.gov/pubmed/30079978.

Yang, D., Denny, S. K., Greenside, P. G., Chaikovsky, A. C., Brady, J. J., Ouadah, Y., Granja, J. M., Jahchan, N. S., Lim, J. S., Kwok, S., Kong, C. S., Berghoff, A. S., Schmitt, A., Reinhardt, H. C., Park, K.-S., Preusser, M., Kundaje, A., Greenleaf, W. J., Sage, J. and Winslow, M. M. (2018). "Intertumoral Heterogeneity in SCLC Is Influenced by the Cell Type of Origin." Cancer Discovery 8(10): 1316-1331. www.ncbi.nlm.nih.gov/pubmed/30228179.

2017

Amer, W., Toth, C., Vassella, E., Meinrath, J., Koitzsch, U., Arens, A., Huang, J., Eischeid, H., Adam, A., Buettner, R., Scheel, A., Schaefer, S. C.Odenthal, M., 2017. Evolution analysis of heterogeneous non-small cell lung carcinoma by ultra-deep sequencing of the mitochondrial genome. Sci Rep, 7(1), 11069. doi.org/10.1038/s41598-017-11345-3

Brägelmann, J., Dammert, M. A., Dietlein, F., Heuckmann, J. M., Choidas, A., Böhm, S., Richters, A., Basu, D., Tischler, V., Lorenz, C., Habenberger, P., Fang, Z., Ortiz-Cuaran, S., Leenders, F., Eickhoff, J., Koch, U., Getlik, M., Termathe, M., Sallouh, M., Greff, Z., Varga, Z., Balke-Want, H., French, C. A., Peifer, M., Reinhardt, H. C., Örfi, L., Kéri, G., Ansén, S., Heukamp, L. C., Büttner, R., Rauh, D., Klebl, B. M., Thomas, R. K.Sos, M. L., 2017. Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. Cell Rep, 20(12), 2833-2845. doi.org/10.1016/j.celrep.2017.08.082

Bührmann, M., Wiedemann, B. M., Müller, M. P., Hardick, J., Ecke, M.Rauh, D., 2017. Structure-based design, synthesis and crystallization of 2-arylquinazolines as lipid pocket ligands of p38α MAPK. PLoS ONE, 12(9), e0184627. doi.org/10.1371/journal.pone.0184627

Büttner, R., Wolf, J., Thomas, R. K.Sos, M. L., 2017. Resistance Mechanisms to AZD9291 and Rociletinib-Response. Clin. Cancer Res., 23(14), 3967-3968. doi.org/10.1158/1078-0432.CCR-17-0948

Doerr, F., George, J., Schmitt, A., Beleggia, F., Rehkämper, T., Hermann, S., Walter, V., Weber, J.-P., Thomas, R. K., Wittersheim, M., Büttner, R., Persigehl, T.Reinhardt, H. C., 2017. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer. Sci Rep, 7(1), 15511. doi.org/10.1038/s41598-017-15840-5

Engel, J., Smith, S., Lategahn, J., Tumbrink, H. L., Goebel, L., Becker, C., Hennes, E., Keul, M., Unger, A., Müller, H., Baumann, M., Schultz-Fademrecht, C., Günther, G., Hengstler, J. G.Rauh, D., 2017. Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor. J. Med. Chem., 60(18), 7725-7744. doi.org/10.1021/acs.jmedchem.7b00515

George, J., Saito, M., Tsuta, K., Iwakawa, R., Shiraishi, K., Scheel, A. H., Uchida, S., Watanabe, S.-I., Nishikawa, R., Noguchi, M., Peifer, M., Jang, S. J., Petersen, I., Büttner, R., Harris, C. C., Yokota, J., Thomas, R. K.Kohno, T., 2017. Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer. Clin. Cancer Res., 23(5), 1220-1226. doi.org/10.1158/1078-0432.CCR-16-1069

Henssen, A. G., Odersky, A., Szymansky, A., Seiler, M., Althoff, K., Beckers, A., Speleman, F., Schäfers, S., De Preter, K., Astrahanseff, K., Struck, J., Schramm, A., Eggert, A., Bergmann, A.Schulte, J. H., 2017. Targeting tachykinin receptors in neuroblastoma. Oncotarget, 8(1), 430-443. doi.org/10.18632/oncotarget.13440

Kaitsiotou, H., Keul, M., Hardick, J., Mühlenberg, T., Ketzer, J., Ehrt, C., Krüll, J., Medda, F., Koch, O., Giordanetto, F., Bauer, S.Rauh, D., 2017. Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT. J. Med. Chem., 60(21), 8801-8815. doi.org/10.1021/acs.jmedchem.7b00841

Knittel, G., Rehkämper, T., Korovkina, D., Liedgens, P., Fritz, C., Torgovnick, A., Al-Baldawi, Y., Al-Maarri, M., Cun, Y., Fedorchenko, O., Riabinska, A., Beleggia, F., Nguyen, P.-H., Wunderlich, F. T., Ortmann, M., Montesinos-Rongen, M., Tausch, E., Stilgenbauer, S., P Frenzel, L., Herling, M., Herling, C., Bahlo, J., Hallek, M., Peifer, M., Buettner, R., Persigehl, T.Reinhardt, H. C., 2017. Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. Nat Commun, 8(1), 153. doi.org/10.1038/s41467-017-00210-6

Lim, S.-Y., Macheleidt, I., Dalvi, P., Schäfer, S. C., Kerick, M., Ozretić, L., Ortiz-Cuaran, S., George, J., Merkelbach-Bruse, S., Wolf, J., Timmermann, B., Thomas, R. K., Schweiger, M. R., Buettner, R.Odenthal, M., 2017. LSD1 modulates the non-canonical integrin β3 signaling pathway in non-small cell lung carcinoma cells. Sci Rep, 7(1), 10292. doi.org/10.1038/s41598-017-09554-x

Malchers, F., Ercanoglu, M., Schütte, D., Castiglione, R., Tischler, V., Michels, S., Dahmen, I., Brägelmann, J., Menon, R., Heuckmann, J. M., George, J., Ansén, S., Sos, M. L., Soltermann, A., Peifer, M., Wolf, J., Büttner, R.Thomas, R. K., 2017. Mechanisms of Primary Drug Resistance inFGFR1-Amplified Lung Cancer. Clin. Cancer Res., 23(18), 5527-5536. doi.org/10.1158/1078-0432.CCR-17-0478

Mollaoglu, G., Guthrie, M. R., Böhm, S., Brägelmann, J., Can, I., Ballieu, P. M., Marx, A., George, J., Heinen, C., Chalishazar, M. D., Cheng, H., Ireland, A. S., Denning, K. E., Mukhopadhyay, A., Vahrenkamp, J. M., Berrett, K. C., Mosbruger, T. L., Wang, J., Kohan, J. L., Salama, M. E., Witt, B. L., Peifer, M., Thomas, R. K., Gertz, J., Johnson, J. E., Gazdar, A. F., Wechsler-Reya, R. J., Sos, M. L.Oliver, T. G., 2017. MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. Cancer Cell. doi.org/10.1016/j.ccell.2016.12.005

Perkhofer, L., Schmitt, A., Romero Carrasco, M. C., Ihle, M., Hampp, S., Ruess, D. A., Hessmann, E., Russell, R., Lechel, A., Azoitei, N., Lin, Q., Liebau, S., Hohwieler, M., Bohnenberger, H., Lesina, M., Algul, H., Gieldon, L., Schrock, E., Gaedcke, J., Wagner, M., Wiesmuller, L., Sipos, B., Seufferlein, T., Reinhardt, H. C., Frappart, P. O.Kleger, A., 2017. ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage. Cancer Res, 77(20), 5576-5590. doi.org/10.1158/0008-5472.CAN-17-0634

Plenker, D., Riedel, M., Brägelmann, J., Dammert, M. A., Chauhan, R., Knowles, P. P., Lorenz, C., Keul, M., Bührmann, M., Pagel, O., Tischler, V., Scheel, A. H., Schütte, D., Song, Y., Stark, J., Mrugalla, F., Alber, Y., Richters, A., Engel, J., Leenders, F., Heuckmann, J. M., Wolf, J., Diebold, J., Pall, G., Peifer, M., Aerts, M., Gevaert, K., Zahedi, R. P., Buettner, R., Shokat, K. M., McDonald, N. Q., Kast, S. M., Gautschi, O., Thomas, R. K.Sos, M. L., 2017. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. Sci Transl Med, 9(394). doi.org/10.1126/scitranslmed.aah6144

Rosswog, C., Schmidt, R., Oberthuer, A., Juraeva, D., Brors, B., Engesser, A., Kahlert, Y., Volland, R., Bartenhagen, C., Simon, T., Berthold, F., Hero, B., Faldum, A.Fischer, M., 2017. Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment. Neoplasia, 19(12), 982-990. doi.org/10.1016/j.neo.2017.09.006

Schmitt, A., Knittel, G., Welcker, D., Yang, T.-P., George, J., Nowak, M., Leeser, U., Büttner, R., Perner, S., Peifer, M.Reinhardt, H. C., 2017. ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma. Cancer Res., 77(11), 3040-3056. doi.org/10.1158/0008-5472.CAN-16-3398

Weischenfeldt, J., Dubash, T., Drainas, A. P., Mardin, B. R., Chen, Y., Stütz, A. M., Waszak, S. M., Bosco, G., Halvorsen, A. R., Raeder, B., Efthymiopoulos, T., Erkek, S., Siegl, C., Brenner, H., Brustugun, O. T., Dieter, S. M., Northcott, P. A., Petersen, I., Pfister, S. M., Schneider, M., Solberg, S. K., Thunissen, E., Weichert, W., Zichner, T., Thomas, R., Peifer, M., Helland, A., Ball, C. R., Jechlinger, M., Sotillo, R., Glimm, H.Korbel, J. O., 2017. Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. Nat. Genet., 49(1), 65-74. doi.org/10.1038/ng.3722

2016

Becker, C., Öcal, S., Nguyen, H. D., Phan, T., Keul, M., Simard, J. R. and Rauh, D. (2016). "Monitoring Conformational Changes in the Receptor Tyrosine Kinase EGFR." ChemBioChem 17(11): 990-994. www.ncbi.nlm.nih.gov/pubmed/26991964.

Bunn, P. A., Minna, J. D., Augustyn, A., Gazdar, A. F., Ouadah, Y., Krasnow, M. A., Berns, A., Brambilla, E., Rekhtman, N., Massion, P. P., Niederst, M., Peifer, M., Yokota, J., Govindan, R., Poirier, J. T., Byers, L. A., Wynes, M. W., McFadden, D. G., MacPherson, D., Hann, C. L., Farago, A. F., Dive, C., Teicher, B. A., Peacock, C. D., Johnson, J. E., Cobb, M. H., Wendel, H.-G., Spigel, D., Sage, J., Yang, P., Pietanza, M. C., Krug, L. M., Heymach, J., Ujhazy, P., Zhou, C., Goto, K., Dowlati, A., Christensen, C. L., Park, K., Einhorn, L. H., Edelman, M. J., Giaccone, G., Gerber, D. E., Salgia, R., Owonikoko, T., Malik, S., Karachaliou, N., Gandara, D. R., Slotman, B. J., Blackhall, F., Goss, G., Thomas, R., Rudin, C. M. and Hirsch, F. R. (2016). "Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?" Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 11(4): 453-474. www.ncbi.nlm.nih.gov/pubmed/26829312.

Engel, J., Becker, C., Lategahn, J., Keul, M., Ketzer, J., Mühlenberg, T., Kollipara, L., Schultz-Fademrecht, C., Zahedi, R. P., Bauer, S. and Rauh, D. (2016). "Inhibition wirkstoffresistenter Mutationsvarianten der Rezeptortyrosinkinase EGFR." Angewandte Chemie: n/a-n/a. onlinelibrary.wiley.com/doi/10.1002/ange.201605011/abstract.

Engel, J., Lategahn, J. and Rauh, D. (2016). "Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer." ACS medicinal chemistry letters 7(1): 2-5. www.ncbi.nlm.nih.gov/pubmed/26819655.

Fernández-Majada, V., Welz, P.-S., Ermolaeva, M. A., Schell, M., Adam, A., Dietlein, F., Komander, D., Büttner, R., Thomas, R. K., Schumacher, B. and Pasparakis, M. (2016). "The tumour suppressor CYLD regulates the p53 DNA damage response." Nature Communications 7: 12508. www.ncbi.nlm.nih.gov/pubmed/27561390.

Henssen, A., Althoff, K., Odersky, A., Beckers, A., Koche, R., Speleman, F., Schäfers, S., Bell, E., Nortmeyer, M., Westermann, F., De Preter, K., Florin, A., Heukamp, L., Spruessel, A., Astrahanseff, K., Lindner, S., Sadowski, N., Schramm, A., Astorgues-Xerri, L., Riveiro, M. E., Eggert, A., Cvitkovic, E. and Schulte, J. H. (2016). "Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition." Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 22(10): 2470-2481. www.ncbi.nlm.nih.gov/pubmed/26631615.

Ikram, F., Ackermann, S., Kahlert, Y., Volland, R., Roels, F., Engesser, A., Hertwig, F., Kocak, H., Hero, B., Dreidax, D., Henrich, K.-O., Berthold, F., Nürnberg, P., Westermann, F. and Fischer, M. (2016). "Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma." Molecular Oncology 10(2): 344-359. www.ncbi.nlm.nih.gov/pubmed/26598443.

Meder, L., König, K., Ozretić, L., Schultheis, A. M., Ueckeroth, F., Ade, C. P., Albus, K., Boehm, D., Rommerscheidt-Fuss, U., Florin, A., Buhl, T., Hartmann, W., Wolf, J., Merkelbach-Bruse, S., Eilers, M., Perner, S., Heukamp, L. C. and Buettner, R. (2016). "NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas." International Journal of Cancer 138(4): 927-938. www.ncbi.nlm.nih.gov/pubmed/26340530.

Ortiz-Cuaran, S., Scheffler, M., Plenker, D., Dahmen, L., Scheel, A. H., Fernandez-Cuesta, L., Meder, L., Lovly, C. M., Persigehl, T., Merkelbach-Bruse, S., Bos, M., Michels, S., Fischer, R., Albus, K., König, K., Schildhaus, H.-U., Fassunke, J., Ihle, M. A., Pasternack, H., Heydt, C., Becker, C., Altmüller, J., Ji, H., Müller, C., Florin, A., Heuckmann, J. M., Nuernberg, P., Ansén, S., Heukamp, L. C., Berg, J., Pao, W., Peifer, M., Buettner, R., Wolf, J., Thomas, R. K. and Sos, M. L. (2016). "Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors." Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 22(19): 4837-4847. www.ncbi.nlm.nih.gov/pubmed/27252416.

Radi, M., Schneider, R., Fallacara, A. L., Botta, L., Crespan, E., Tintori, C., Maga, G., Kissova, M., Calgani, A., Richters, A., Musumeci, F., Rauh, D. and Schenone, S. (2016). "A cascade screening approach for the identification of Bcr-Abl myristate pocket binders active against wild type and T315I mutant." Bioorganic & Medicinal Chemistry Letters 26(15): 3436-3440. www.ncbi.nlm.nih.gov/pubmed/27374241.

Ribeiro, D., Klarqvist, M. D. R., Westermark, U. K., Oliynyk, G., Dzieran, J., Kock, A., Savatier Banares, C., Hertwig, F., Johnsen, J. I., Fischer, M., Kogner, P., Lovén, J. and Arsenian Henriksson, M. (2016). "Regulation of Nuclear Hormone Receptors by MYCN-Driven miRNAs Impacts Neural Differentiation and Survival in Neuroblastoma Patients." Cell Reports 16(4): 979-993. www.ncbi.nlm.nih.gov/pubmed/27396325.

Thompson, D., Vo, K. T., London, W. B., Fischer, M., Ambros, P. F., Nakagawara, A., Brodeur, G. M., Matthay, K. K. and DuBois, S. G. (2016). "Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project." Cancer 122(6): 935-945. www.ncbi.nlm.nih.gov/pubmed/26709890.

Weiskopf, K., Jahchan, N. S., Schnorr, P. J., Cristea, S., Ring, A. M., Maute, R. L., Volkmer, A. K., Volkmer, J.-P., Liu, J., Lim, J. S., Yang, D., Seitz, G., Nguyen, T., Wu, D., Jude, K., Guerston, H., Barkal, A., Trapani, F., George, J., Poirier, J. T., Gardner, E. E., Miles, L. A., de Stanchina, E., Lofgren, S. M., Vogel, H., Winslow, M. M., Dive, C., Thomas, R. K., Rudin, C. M., van de Rijn, M., Majeti, R., Garcia, K. C., Weissman, I. L. and Sage, J. (2016). "CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer." The Journal of Clinical Investigation 126(7): 2610-2620. www.ncbi.nlm.nih.gov/pubmed/27294525.

2015

Basu, D., Richters, A., Rauh, D., 2015. Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR. Bioorg. Med. Chem. 23, 2767–2780. doi.org/10.1016/j.bmc.2015.04.038

Carter, D.R., Murray, J., Cheung, B.B., Gamble, L., Koach, J., Tsang, J., Sutton, S., Kalla, H., Syed, S., Gifford, A.J., Issaeva, N., Biktasova, A., Atmadibrata, B., Sun, Y., Sokolowski, N., Ling, D., Kim, P.Y., Webber, H., Clark, A., Ruhle, M., Liu, B., Oberthuer, A., Fischer, M., Byrne, J., Saletta, F., Thwe, L.M., Purmal, A., Haderski, G., Burkhart, C., Speleman, F., De Preter, K., Beckers, A., Ziegler, D.S., Liu, T., Gurova, K.V., Gudkov, A.V., Norris, M.D., Haber, M., Marshall, G.M., 2015. Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. Sci Transl Med 7, 312ra176. doi.org/10.1126/scitranslmed.aab1803

Dietlein, F., Kalb, B., Jokic, M., Noll, E.M., Strong, A., Tharun, L., Ozretić, L., Künstlinger, H., Kambartel, K., Randerath, W.J., Jüngst, C., Schmitt, A., Torgovnick, A., Richters, A., Rauh, D., Siedek, F., Persigehl, T., Mauch, C., Bartkova, J., Bradley, A., Sprick, M.R., Trumpp, A., Rad, R., Saur, D., Bartek, J., Wolf, J., Büttner, R., Thomas, R.K., Reinhardt, H.C., 2015. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer. Cell 162, 146–159. doi.org/10.1016/j.cell.2015.05.053

Engel, J., Richters, A., Getlik, M., Tomassi, S., Keul, M., Termathe, M., Lategahn, J., Becker, C., Mayer-Wrangowski, S., Grütter, C., Uhlenbrock, N., Krüll, J., Schaumann, N., Eppmann, S., Kibies, P., Hoffgaard, F., Heil, J., Menninger, S., Ortiz-Cuaran, S., Heuckmann, J.M., Tinnefeld, V., Zahedi, R.P., Sos, M.L., Schultz-Fademrecht, C., Thomas, R.K., Kast, S.M., Rauh, D., 2015. Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach. J. Med. Chem. 58, 6844–6863. doi.org/10.1021/acs.jmedchem.5b01082

Fang, Z., Simard, J.R., Plenker, D., Nguyen, H.D., Phan, T., Wolle, P., Baumeister, S., Rauh, D., 2015. Discovery of inter-domain stabilizers-a novel assay system for allosteric akt inhibitors. ACS Chem. Biol. 10, 279–288. doi.org/10.1021/cb500355c

Fernandez-Cuesta, L., Sun, R., Menon, R., George, J., Lorenz, S., Meza-Zepeda, L.A., Peifer, M., Plenker, D., Heuckmann, J.M., Leenders, F., Zander, T., Dahmen, I., Koker, M., Schöttle, J., Ullrich, R.T., Altmüller, J., Becker, C., Nürnberg, P., Seidel, H., Böhm, D., Göke, F., Ansén, S., Russell, P.A., Wright, G.M., Wainer, Z., Solomon, B., Petersen, I., Clement, J.H., Sänger, J., Brustugun, O.-T., Helland, Å., Solberg, S., Lund-Iversen, M., Buettner, R., Wolf, J., Brambilla, E., Vingron, M., Perner, S., Haas, S.A., Thomas, R.K., 2015. Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biol. 16, 7. doi.org/10.1186/s13059-014-0558-0

Fey, D., Halasz, M., Dreidax, D., Kennedy, S.P., Hastings, J.F., Rauch, N., Munoz, A.G., Pilkington, R., Fischer, M., Westermann, F., Kolch, W., Kholodenko, B.N., Croucher, D.R., 2015. Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients. Sci Signal 8, ra130. doi.org/10.1126/scisignal.aab0990

George, J., Lim, J.S., Jang, S.J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X., Fernández-Cuesta, L., Bosco, G., Müller, C., Dahmen, I., Jahchan, N.S., Park, K.-S., Yang, D., Karnezis, A.N., Vaka, D., Torres, A., Wang, M.S., Korbel, J.O., Menon, R., Chun, S.-M., Kim, D., Wilkerson, M., Hayes, N., Engelmann, D., Pützer, B., Bos, M., Michels, S., Vlasic, I., Seidel, D., Pinther, B., Schaub, P., Becker, C., Altmüller, J., Yokota, J., Kohno, T., Iwakawa, R., Tsuta, K., Noguchi, M., Muley, T., Hoffmann, H., Schnabel, P.A., Petersen, I., Chen, Y., Soltermann, A., Tischler, V., Choi, C., Kim, Y.-H., Massion, P.P., Zou, Y., Jovanovic, D., Kontic, M., Wright, G.M., Russell, P.A., Solomon, B., Koch, I., Lindner, M., Muscarella, L.A., la Torre, A., Field, J.K., Jakopovic, M., Knezevic, J., Castaños-Vélez, E., Roz, L., Pastorino, U., Brustugun, O.-T., Lund-Iversen, M., Thunnissen, E., Köhler, J., Schuler, M., Botling, J., Sandelin, M., Sanchez-Cespedes, M., Salvesen, H.B., Achter, V., Lang, U., Bogus, M., Schneider, P.M., Zander, T., Ansén, S., Hallek, M., Wolf, J., Vingron, M., Yatabe, Y., Travis, W.D., Nürnberg, P., Reinhardt, C., Perner, S., Heukamp, L., Büttner, R., Haas, S.A., Brambilla, E., Peifer, M., Sage, J., Thomas, R.K., 2015. Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47–53. doi.org/10.1038/nature14664

Lindner, S., Bachmann, H.S., Odersky, A., Schaefers, S., Klein-Hitpass, L., Hero, B., Fischer, M., Eggert, A., Schramm, A., Schulte, J.H., 2015. Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma. Biomed Rep 3, 443–446. doi.org/10.3892/br.2015.463

Mayer-Wrangowski, S.C., Rauh, D., 2015. Monitoring ligand-induced conformational changes for the identification of estrogen receptor agonists and antagonists. Angew. Chem. Int. Ed. Engl. 54, 4379–4382. doi.org/10.1002/anie.201410148

Peifer, M., Hertwig, F., Roels, F., Dreidax, D., Gartlgruber, M., Menon, R., Krämer, A., Roncaioli, J.L., Sand, F., Heuckmann, J.M., Ikram, F., Schmidt, R., Ackermann, S., Engesser, A., Kahlert, Y., Vogel, W., Altmüller, J., Nürnberg, P., Thierry-Mieg, J., Thierry-Mieg, D., Mariappan, A., Heynck, S., Mariotti, E., Henrich, K.-O., Gloeckner, C., Bosco, G., Leuschner, I., Schweiger, M.R., Savelyeva, L., Watkins, S.C., Shao, C., Bell, E., Höfer, T., Achter, V., Lang, U., Theissen, J., Volland, R., Saadati, M., Eggert, A., de Wilde, B., Berthold, F., Peng, Z., Zhao, C., Shi, L., Ortmann, M., Büttner, R., Perner, S., Hero, B., Schramm, A., Schulte, J.H., Herrmann, C., O’Sullivan, R.J., Westermann, F., Thomas, R.K., Fischer, M., 2015. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 526, 700–704. doi.org/10.1038/nature14980

Richters, A., Basu, D., Engel, J., Ercanoglu, M.S., Balke-Want, H., Tesch, R., Thomas, R.K., Rauh, D., 2015. Identification and further development of potent TBK1 inhibitors. ACS Chem. Biol. 10, 289–298. doi.org/10.1021/cb500908d

Scheffler, M., Merkelbach-Bruse, S., Bos, M., Fassunke, J., Gardizi, M., Michels, S., Groneck, L., Schultheis, A.M., Malchers, F., Leenders, F., Kobe, C., König, K., Heukamp, L.C., Sos, M.L., Thomas, R.K., Büttner, R., Wolf, J., 2015. Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient. J Thorac Oncol 10, e40-43. doi.org/10.1097/JTO.0000000000000503

Schramm, A., Köster, J., Assenov, Y., Althoff, K., Peifer, M., Mahlow, E., Odersky, A., Beisser, D., Ernst, C., Henssen, A.G., Stephan, H., Schröder, C., Heukamp, L., Engesser, A., Kahlert, Y., Theissen, J., Hero, B., Roels, F., Altmüller, J., Nürnberg, P., Astrahantseff, K., Gloeckner, C., De Preter, K., Plass, C., Lee, S., Lode, H.N., Henrich, K.-O., Gartlgruber, M., Speleman, F., Schmezer, P., Westermann, F., Rahmann, S., Fischer, M., Eggert, A., Schulte, J.H., 2015. Mutational dynamics between primary and relapse neuroblastomas. Nat. Genet. 47, 872–877. doi.org/10.1038/ng.3349

Schultheis, A.M., Scheel, A.H., Ozretić, L., George, J., Thomas, R.K., Hagemann, T., Zander, T., Wolf, J., Buettner, R., 2015. PD-L1 expression in small cell neuroendocrine carcinomas. Eur. J. Cancer 51, 421–426. doi.org/10.1016/j.ejca.2014.12.006

Weisner, J., Gontla, R., van der Westhuizen, L., Oeck, S., Ketzer, J., Janning, P., Richters, A., Mühlenberg, T., Fang, Z., Taher, A., Jendrossek, V., Pelly, S.C., Bauer, S., van Otterlo, W.A.L., Rauh, D., 2015. Covalent-Allosteric Kinase Inhibitors. Angew. Chem. Int. Ed. Engl. 54, 10313–10316. doi.org/10.1002/anie.201502142

2014

 

Richters, A., Nguyen, H.D., Phan, T., Simard, J.R., Grütter, C., Engel, J., Rauh, D., 2014. Identification of type II and III DDR2 inhibitors. J. Med. Chem. 57, 4252–4262. doi.org/10.1021/jm500167q

 

SMOOSE-Projekte in den Medien: